To study the clinical effect of tranexamic acid combined with hemocoagulase bothrops atrox on preventing hematoma enlargement after traumatic cerebral hemorrhage.

One hundred and thirty-six exception injury after cerebral hemorrhage patients admitted to District 1 of Neurosurgery Department of Wuchuan People’s Hospital and Affiliated Hospital of Guangdong Medical University from January 2016 to December 2017 were selected as the research object, and they were randomly divided into experimental group and control group, 68 cases respectively. Control group were given hemocoagulase bothrops atrox, experiment group were given hemocoagulase bothrops atrox combination of tranexamic acid. Then compare two groups of patients with cerebral hemorrhage haematoma increases the incidence of differences, treatment efficacy and complications, and clinical outcomes.

In the experimental group, hematoma continued to increase and reached the operation indication (3 cases, 1 case) were significantly less than the control group (10 cases, 8 cases), the differences were statistically significant (P<0.05). CT examination of the patient’s head showed that the amount of hematoma in the experimental group was gradually absorbed, and the hematoma surrounding edema was lighter than that in the control group. The incidence of pulmonary infection and bedsore in the experimental group was significantly lower than that in the control group (P<0.05), but there was no significant difference in deep vein infection, urinary tract infection and malnutrition (P>0.05). The ADL scores of the experimental group was significantly higher than that of the control group at the 3^rd, 6^th and 9^th month of the recovery period (P<0.05).

Tranexamic acid combined with hemocoagulase bothrops atrox can reduce the incidence of intracerebral hemorrhage hematoma after traumatic brain injury and improve the clinical treatment effect.